QUINTESSENTIAL-2: A phase 3 study comparing efficacy and safety of arlocabtagene autoleucel (arlo-cel) versus standard regimens in adult patients with relapsed or refractory multiple myeloma (RRMM) refractory to lenalidomide.

Authors: Rakesh Popat, Sarah Marie Larson, Asya Varshavsky Yanovsky, Susan Bal, Marc-Steffen Raab, Kimberly Grazioli, Debashree Basudhar, Hongxiang Hu, Ya Meng, Lamis Eldjerou, Simon J. Harrison, Paula Rodríguez-Otero

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps7564

Source: Full article

---

Abstract

TPS7564